Prime Therapeutics’ leading research shows only 1 in 12 remain on a GLP-1 drug for obesity at three years
Neal Tepel
October 15, 2025
Individuals who took a high-potency GLP-1 drug approved for obesity — such as semaglutide (Wegovy®), which is now more commonly used to treat the condition — had greater persistence at 14% three years after initiating therapy.
